CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment

Reuters

05/20

CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment

CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536669370"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536669370\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536669370?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 12:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536669370","market":"us","top_or_hot":-1,"title":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 12:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL7tFCFL:1","article_id":"2536669370","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536669370","pubTimestamp":1747715047,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta  in China for Gaucher Disease Treatment. CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection , has received marketing approval from the National Medical Products Administration  of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUB","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","01228":"北海康成-B"},"translate_title":"CANbridge Pharmaceuticals Inc.在中国获得Velaglucerase-beta（Gaurunning，CAN103）用于治疗戈谢病的上市许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01228":0.9},"content_text":"CANbridge Pharmaceuticals Inc. Secures Marketing Approval for Velaglucerase-beta (Gaurunning, CAN103) in China for Gaucher Disease Treatment\n    \n\n        CANbridge Pharmaceuticals Inc., a global biopharmaceutical company based in the People's Republic of China, has announced that its drug, velaglucerase-beta for injection (Gaurunning, CAN103), has received marketing approval from the National Medical Products Administration (NMPA) of the PRC. The approval, granted on May 15, 2025, allows the use of the drug for the treatment of type I and III Gaucher disease. CANbridge Pharmaceuticals holds the global proprietary rights to develop and commercialize this product. Despite this significant milestone, the company cautions that there is no guarantee of successful commercialization. The company remains dedicated to advancing transformative therapies for rare diseases, with a robust pipeline addressing unmet needs in various conditions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Canbridge Pharmaceuticals Inc. published the original content used to generate this news brief on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}